Advertisement

International Journal of Clinical Oncology

, Volume 20, Issue 1, pp 198–206 | Cite as

Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial

  • Naohito ShimoyamaEmail author
  • Ikuo Gomyo
  • Nobuyuki Katakami
  • Masakuni Okada
  • Nobuyuki Yukitoshi
  • Eri Ohta
  • Megumi Shimoyama
Original Article

Abstract

Background

Breakthrough cancer pain typically has a rapid onset and relatively short duration. Due to this temporal profile, it may not be adequately relieved by oral opioid analgesics. The sublingual fentanyl orally disintegrating tablet is a formulation by which fentanyl can be rapidly absorbed across the oral mucosa producing rapid-onset analgesia, and which may be effective for breakthrough pain treatment.

Methods

A multicenter, randomized, placebo-controlled, double-blind comparative study was conducted to evaluate the efficacy and safety of the sublingual fentanyl tablet at optimized doses for breakthrough pain treatment in cancer patients treated with strong opioid analgesics at fixed intervals. The optimal dose was determined by open-label dose titration. The efficacy and safety of a 12-week extended treatment were also evaluated.

Results

Eleven of 42 subjects who received the sublingual fentanyl tablet experienced adverse drug reactions. Common reactions were somnolence, constipation, nausea, and vomiting. No serious adverse reactions occurred. Sublingual fentanyl tablets at optimal doses and placebo were administered to 37 subjects in a double-blinded manner. A significant analgesic effect of the sublingual fentanyl tablet was present compared to placebo at 30 min after administration. The sublingual fentanyl tablet was also effective and safe during extended treatment, in which changes in basal opioid doses as well as sublingual fentanyl tablet doses were made as needed.

Conclusion

Sublingual fentanyl tablets at doses determined by titration were effective and safe for breakthrough pain treatment in cancer patients treated with strong opioid analgesics at fixed intervals. Extended treatment up to 12 weeks was also effective and safe.

Keywords

Breakthrough pain Cancer pain Sublingual fentanyl tablet Opioid Dose titration 

Notes

Acknowledgments

The sponsor of this clinical trial was Kyowa Hakko Kirin, Co., Ltd.

Conflict of interest

During the past 3 years, Naohito Shimoyama has had a contract as a medical expert with Kyowa Hakko Kirin Co., Ltd., Nippon Kayaku Co., Ltd. and Mitsubishi Tanabe Pharma Corporation. Naohito Shimoyama also has had a contract with Teikoku Seiyaku Co., Ltd. as a coordinating investigator and a member of independent data monitoring committee. Nobuyuki Yukitoshi and Eri Ohta are employees of Kyowa Hakko Kirin Co., Ltd. The other authors have no conflicts of interest to report.

References

  1. 1.
    Potenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273–281CrossRefGoogle Scholar
  2. 2.
    Simmonds MA (1999) Management of breakthrough pain due to cancer. Oncology (Williston Park) 13:1103–1108Google Scholar
  3. 3.
    Bennett D, Burton AW, Fishman S et al (2005) Consensus panel recommendations for the assessment and management of breakthrough pain: Part 2. Management. Pharmacol Ther 30:354–361Google Scholar
  4. 4.
    Actiq SPC (2012) Cephalon Ltd, UKGoogle Scholar
  5. 5.
    Bredenberg S, Duberg M, Lennernas B et al (2003) In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 20:327–334PubMedCrossRefGoogle Scholar
  6. 6.
    Streisand JB, Busch MA, Egan TD et al (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88:305–309PubMedCrossRefGoogle Scholar
  7. 7.
    Lennernas B, Hedner T, Holmberg M et al (2004) Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 59:249–253CrossRefGoogle Scholar
  8. 8.
    England R, Maddocks M, Manderson C et al (2011) How practical are transmucosal fentanyl products for breakthrough cancer pain? novel use of placebo formulations to survey user opinion. BMJ Support Palliat Care 1:349–351PubMedCrossRefGoogle Scholar
  9. 9.
    Christie JM, Simmonds M, Patt R et al (1998) Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 16:3238–3245PubMedGoogle Scholar
  10. 10.
    Payne R, Coluzzi P, Hart L et al (2011) Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manag 22:575–583CrossRefGoogle Scholar
  11. 11.
    Cherny NI, Portenoy RK (1993) Cancer pain management: current strategy. Cancer 72(Suppl 11):3393–3415PubMedCrossRefGoogle Scholar
  12. 12.
    Yamaguchi T, Shima Y, Morita T et al (2013) Clinical guideline for pharmacological management of cancer pain: the Japanese society of palliative medicine recommendations. Jpn J Clin Oncol 43:896–909PubMedCrossRefGoogle Scholar
  13. 13.
    Rauck RL, Tark M, Reyes E et al (2009) Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 25:2877–2885PubMedCrossRefGoogle Scholar
  14. 14.
    Abstral SPC (2013) ProStrakan Ltd, Galashiels, UKGoogle Scholar
  15. 15.
    Abstral SPC (2013) Galena Biopharma, Inc., Lake Oswego, USGoogle Scholar
  16. 16.
    Todd KH, Funk JP (1996) The minimum clinically important difference in physician-assigned visual analog pain scores. Acad Emerg Med 3:142–146PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2014

Authors and Affiliations

  • Naohito Shimoyama
    • 1
    Email author
  • Ikuo Gomyo
    • 2
    • 3
  • Nobuyuki Katakami
    • 4
  • Masakuni Okada
    • 5
    • 6
  • Nobuyuki Yukitoshi
    • 7
  • Eri Ohta
    • 8
  • Megumi Shimoyama
    • 9
  1. 1.Department of Palliative MedicineThe Jikei University School of MedicineTokyoJapan
  2. 2.Department of Palliative MedicineSaito Yukoukai HospitalIbarakiJapan
  3. 3.Department of Palliative MedicineJapanese Red Cross Kitami HospitalKitamiJapan
  4. 4.Division of Integrated Oncology, Foundation for Biomedical Research and InnovationInstitute of Biomedical Research and Innovation HospitalKobeJapan
  5. 5.Department of Internal MedicineShakaihoken Kobe Central HospitalKobeJapan
  6. 6.Okada Internal Medicine ClinicKobeJapan
  7. 7.Development Division, Clinical Development Department 2Kyowa Hakko Kirin Co., Ltd.TokyoJapan
  8. 8.Development Division, Clinical Data Evaluation DepartmentKyowa Hakko Kirin Co., Ltd.TokyoJapan
  9. 9.Department of AnesthesiologyTeikyo University Chiba Medical CenterIchiharaJapan

Personalised recommendations